Fennec banks positive results on heels of move to Nasdaq

On the heels of making its Nasdaq debut – moving from an over-the-counter market it started trading on several years ago – Research Triangle Park-based Fennec Pharmaceuticals (Nasdaq: FENC) has banked positive Phase 3 results for its product for the prevention of hearing loss in pediatric cancer patients receiving chemotherapy. The P hase 3 results – for Fennec’s sodium thiosulfate therapy called PEDMARK – were presented at the International Society of Pediatric Oncology (SIOP) 2017 meeting…
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Source Type: news